Novartis AG Common Stock (NY:NVS)

141.00 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

59 60 Next >

NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff ↗

September 15, 2023

Novartis (NVS) stock is rising higher on Friday after the company announced approval for the spinoff of its generic drugs business Sandoz.

Via InvestorPlace

Instacart Mulls IPO Price Hike After Arm's Stellar Debut, UAW Launches Historic Simultaneous Strike, China Sanctions Lockheed Martin & Northrop Grumman Concerning Taiwan Arms Sales: Today's Top Stories ↗

September 15, 2023

Wall Street Journal

Via Benzinga

Topics Initial Public Offering

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off ↗

September 15, 2023

At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders

Via Benzinga

2 Dividend Stocks to Buy and Hold Forever ↗

September 13, 2023

These companies' prospects look secure.

Via The Motley Fool

Price Over Earnings Overview: Novartis ↗

September 01, 2023

Via Benzinga

Peering Into Novartis's Recent Short Interest ↗

August 31, 2023

Via Benzinga

AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗

September 11, 2023

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....

Via Benzinga

Topics Artificial Intelligence

Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories ↗

September 11, 2023

Benzinga Qualcomm Announces Chip Supply Agreement With Apple

Via Benzinga

Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis ↗

September 11, 2023

Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has

Via Benzinga

AI 2.0 is Here: How to Invest in a Generational Opportunity

September 08, 2023

AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it.

Via MarketBeat

Topics Artificial Intelligence Supply Chain

Could This Biosimilar Drug Be Novartis' Next Blockbuster? ↗

September 05, 2023

Novartis expects to submit regulatory applications for its biosimilar soon.

Via The Motley Fool

8 Pharma Stocks Affected by New Drug Price Negotiation Rules ↗

September 02, 2023

Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?

Via The Motley Fool

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

September 01, 2023

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

Via MarketBeat

Topics Economy

Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet ↗

August 31, 2023

The Biden administration's move to lower drug prices has prompted a flurry of legal challenges.

Via Benzinga

Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck

August 30, 2023

Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027

Via SBWire

What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks? ↗

August 29, 2023

Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.

Via The Motley Fool

Transdermal Drug Patches Market to See Huge Growth : Novartis, Mylan, Accrux

August 29, 2023

Stay up-to-date with Transdermal Drug Patches Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts ↗

August 29, 2023

To gain an edge, this is what you need to know today.

Via Benzinga

Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle ↗

August 29, 2023

The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including:

Via Benzinga

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts ↗

August 29, 2023

The Biden administration is planning to negotiate the prices of 10 drugs in 2026.

Via Investor's Business Daily

3 AI Stocks With the Potential to Transform Your Financial Future ↗

August 28, 2023

Are you looking to invest in AI stocks? Here are three picks with the potential to transform your financial future.

Via InvestorPlace

Topics Artificial Intelligence

3 Emerging Market Stocks to Buy in August ↗

August 28, 2023

These three emerging market stocks to buy in August will have very strong, positive catalysts going forward.

Via InvestorPlace

Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest ↗

August 24, 2023

Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...

Via Benzinga

Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz ↗

August 24, 2023

CVS Health Corp (NYSE: CVS) has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar

Via Benzinga

Could This Medicine Be the Next Winner for Novartis? ↗

August 23, 2023

The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.

Via The Motley Fool

Gold Rush In Weight Loss Industry Impacts Retailers With Pharmacy Businesses ↗

August 22, 2023

Retailers with pharmacy businesses, including major players like Walmart Inc (NYSE: WMT), Kroger Company (NYSE: KR), and Rite Aid Corp (NYSE:

Via Benzinga

A Comprehensive Study Exploring Breast Cancer Drugs Market : Key Players- Sanofi, Novartis, Lilly ↗

August 21, 2023

The Global Breast Cancer Drugs Market offers energetic visions to conclude market size, opportunities, growth pattern, and competitive surroundings. The research is derived through primary and...

Via SBWire

Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms ↗

August 21, 2023

The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.

Via Investor's Business Daily

SpaceX On Par With Intel, Disney; US Weight Loss Drugs Pricier; Moderna, Pfizer's Shot Effective Against New Variant: Today's Top Stories ↗

August 18, 2023

Benzinga

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.